Ewing sarcoma trials

AI-generated summary

The trial tests whether regorafenib given as maintenance therapy after first-line treatment helps keep bone sarcoma from coming back. Participants are patients 12 years and older with confirmed primary bone sarcoma who have completed standard treatment and have no evidence of disease; they are randomized to regorafenib for up to 12 months or to placebo surveillance. The main goal is to see if regorafenib improves relapse-free survival and disease control, with results analyzed by high-risk versus low-risk relapse groups. Key exclusions include prior VEGFR inhibitors, certain cardiovascular problems, active infections, HIV, hepatitis B/C, pregnancy, and other conditions that could affect safety or adherence. The study is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SABRE tests autologous CAR-T cells targeting B7-H3, combined with DNR-PRAME tumor antigen–specific T cells, given after lymphodepleting chemotherapy in children and young people with relapsed or refractory rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, or Wilms tumor. It is a phase I dose-escalation study to determine safety and feasibility and to find the maximum tolerated dose by monitoring dose-limiting toxicities during the first 28 days after infusion. Up to 18 participants aged 1 to under 24 years will receive three dose levels and be followed during hospitalization and for at least 1 year, with longer follow-up planned. Key exclusions include known CNS disease, uncontrolled infection or HIV, pregnancy, and prior allogeneic stem cell transplant, among other safety criteria.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests INBRX-109, a DR5-targeting antibody, in people with locally advanced or metastatic solid tumors, including sarcomas. It is a first-in-human, open-label, three-part phase 1 study to assess safety and to determine a dose for future use. Eligible participants include people aged 12-84 with Ewing sarcoma and 18-84 with other tumors, all with measurable disease; there are expansion groups for Ewing sarcoma with the classical fusion and for colorectal adenocarcinoma with limited prior therapy. Exclusions include prior DR5 agonist treatment, recent anticancer therapy, active liver disease, and active CNS tumors or HIV/HBV/HCV infection. The study is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests lurbinectedin used alone to treat pediatric and young adult participants with relapsed or refractory Ewing sarcoma (and, in Phase 1, other previously treated solid tumors). The trial has two parts: Phase 1 will look at safety, tolerability, how the drug behaves in the body, the recommended Phase 2 dose, and initial effectiveness; Phase 2 will further assess how well it works and its safety in the target group. Eligible participants are children and young adults roughly aged 2 to 30 with a confirmed solid tumor and adequate organ function and general health. Important exclusions include QT prolongation, active CNS metastases requiring steroids, significant uncontrolled illness or recent intensive therapy, prior lurbinectedin or trial drugs, and recent live vaccines.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a single-arm, multi-center trial testing romiplostim as a supportive care measure for patients with a new diagnosis of Ewing sarcoma receiving interval‑compressed chemotherapy. - It aims to learn whether romiplostim can prevent chemotherapy-induced thrombocytopenia (low platelets), whether it is safe to use with upfront Ewing sarcoma treatment, and whether it can be feasibly incorporated into standard regimens. - Eligible participants are patients over 1 year old with a new Ewing sarcoma diagnosis who are treated with interval‑compressed chemotherapy, and their informed consent (and assent when appropriate) is required. - Key exclusions include bone marrow–metastatic disease, certain extensive bone marrow–directed radiation or procedures, prior use of romiplostim or other platelet‑producing agents, and a history of immune thrombocytopenia–related treatments or related hematologic conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a combo of AMXT 1501 and DFMO (eflornithine) in children and young adults up to age 21 with relapsed or refractory neuroblastoma, certain brain tumors (including DIPG), and some sarcomas. - The main goals are to find a safe, recommended dose of AMXT 1501 with DFMO, assess safety and tolerability, and learn whether the treatment shows activity by looking at responses and how long the disease stays under control. - The trial includes different age groups (adolescents and young adults 12 and older, and younger children under 12) with age-specific dose considerations. - Key exclusions include body surface area under 0.25 m2, current use of other investigational or anticancer drugs, active infection, or risk factors that would make safety monitoring unreliable.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study will look at the molecular, cellular, and genetic features of several pediatric solid tumors (including neuroblastoma, osteosarcoma, retinoblastoma, Ewing sarcoma, soft tissue sarcomas, adrenocortical tumors, and liver cancers) using gene expression analysis, SNP/genomic testing, CGH, sequencing, and electron microscopy, and it will also create tumor cell lines and animal tumor models. It will study how T cells recognize tumors by comparing T cell receptors from blood and from tumor tissue, and it will examine methylation patterns and anti-tumor T cell responses before and after PD-1 inhibition. Eligible participants are children and young adults up to age 25 with suspected or known diagnoses of these cancers, from whom tissue may be collected at biopsy, surgery, bone marrow aspiration, or relapse, with informed consent at St. Jude or collaborating sites. Exclusion: patients who are positive for Hepatitis B, Hepatitis C, or HIV.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- Mayo Clinic is testing three treatments—carbon ion therapy, surgery, and proton therapy—for pelvic bone sarcomas in people aged 15 and older who have newly diagnosed tumors and no distant metastases. - The study aims to see if carbon ion therapy improves patients’ reported quality of life compared with surgery, and whether it provides better local disease control than proton therapy. - Participants will fill out quality-of-life questionnaires before therapy, 2–4 months after therapy, 5–9 months after completion, and then annually for up to five years. - Key exclusions include receiving palliative treatment, recurrent disease, age under 15, prior radiation to the treatment area, distant metastases, benign pelvic bone tumors, and pregnancy or inability/unwillingness to consent or complete questionnaires.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial is testing two detection methods, RT-qPCR and ddPCR, to find minimal residual disease in cryopreserved ovarian or testicular tissue. It focuses on tissues from children who were treated for neuroblastoma or Ewing sarcoma during infancy. The goal is to compare the sensitivity and specificity of these methods to identify tumor cells and determine the most reliable approach for safe future use of the preserved tissue. There are no exclusion criteria listed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests PET imaging using a radioactive form of methionine to evaluate tumors in children and young adults with cancer. It aims to find out how often MET PET can visualize tumors at diagnosis and whether MET uptake relates to tumor grade. The study also looks at how MET distributes in normal organs and how MET PET findings compare with MRI and FDG-PET CT over time. The trial is sponsored by St. Jude Children’s Research Hospital and is currently active but not recruiting. Eligible participants are patients under St. Jude care with known or suspected cancer; key exclusions include having more than six MET PET scans in the past year or an inability to give informed consent (and lactation in women of childbearing age).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a longitudinal cohort study to see if cancer treatment accelerates early aging in adolescents and young adults with cancer, by measuring aging markers before therapy and one year later. It includes patients aged 18-39 with a confirmed cancer diagnosis who are about to start systemic therapy with curative intent. The main goal is to see how the senescence marker P16 changes over one year, and it also looks at SASP, vascular markers, and cardiovascular risk factors related to treatment and patient/tumor characteristics. Measurements are taken at two visits and include blood tests and a physical exam (weight, height, waist-hip ratio, blood pressure); key exclusions are inability to understand consent, treatment with immune checkpoint inhibitors or anti-angiogenic therapy, and prior systemic therapy or radiotherapy for another cancer (with limited exceptions).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This pediatric MATCH trial tests the drug ivosidenib (AG-120) in children and adolescents with advanced solid tumors, CNS tumors, lymphomas, or histiocytic disorders that have IDH1 mutations and have not responded to prior treatment. The study aims to see how often tumors shrink or disappear (objective response rate) and to learn about progression-free survival and safety in this group. Participants are aged 12 months to 21 years and must have measurable disease along with other health criteria. Ivosidenib is given by mouth once daily in 28-day cycles, for up to 2 years, to study its pharmacology and biomarkers of response. Key exclusions include pregnancy or breastfeeding, use of strong CYP3A4 inhibitors or inducers, prior exposure to IDH1 inhibitors, and receiving another investigational or anti-cancer drug at enrollment.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests weekly irinotecan liposomes in people with relapsed or metastatic Ewing sarcoma to see if it is safe and whether it can help control the cancer. - It is for patients whose disease has recurred or progressed after standard first-line chemotherapy and who have measurable disease and adequate organ function. - The trial uses a Bayesian dose-finding design to identify an appropriate weekly dose. - Key exclusions include QTc prolongation over 480 ms, pregnancy or breastfeeding, known allergy to irinotecan liposomes, and having another active cancer or a serious uncontrolled illness.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This phase Ib trial is testing whether regorafenib can be given safely with the standard chemotherapy for newly diagnosed Ewing sarcoma that has spread to multiple sites beyond the lungs or pleura. - It is for patients aged 2 to under 50 who have metastatic disease and are fit to receive the full multimodal treatment. - The study aims to find out if adding regorafenib is feasible and how to dose it during induction chemotherapy and consolidation chemotherapy, using different dose levels and timing around surgery or radiotherapy. - Key exclusions include disease limited to the lungs/pleura, pregnancy, prior ES treatment other than surgery, significant heart problems or uncontrolled high blood pressure, and other health issues that could interfere with treatment. - The trial is currently not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This pediatric MATCH trial tests selpercatinib, an RET pathway inhibitor, in children and adolescents with advanced solid tumors, lymphomas, or histiocytic disorders that have activating RET gene alterations. The study aims to learn how often tumors shrink or disappear (objective response rate) and how long patients stay progression-free, as well as how tolerable the drug is. Participants are ages 12 months to 21 years with measurable disease and must have recovered from prior therapy; they must not have previously received selpercatinib or other RET inhibitors. Selpercatinib is given by mouth twice daily in 28-day cycles for up to 26 cycles (about 2 years), with regular imaging and safety monitoring. Key exclusions include pregnancy, certain drug interactions (e.g., strong CYP3A4 inhibitors/inducers), recent major surgery, active infection, and uncontrolled medical conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This pediatric MATCH trial tests tipifarnib in children and young people aged 12 months to 21 years whose advanced solid tumors, lymphoma, or histiocytic disorders have an HRAS gene alteration. - The main goal is to see how many patients have a tumor shrinkage or disappearance (objective response) with tipifarnib. - The study also looks at progression-free survival and how well the drug is tolerated in kids and teens. - It will explore biomarkers that might predict who responds and how tumor DNA in blood changes over time. - Key exclusions include pregnancy or breastfeeding, and not being eligible if you’re on other investigational drugs or certain interacting medications.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This randomized study tests whether adding ganitumab, a drug that blocks the IGF-1R pathway, to standard multiagent chemotherapy improves outcomes for newly diagnosed metastatic Ewing sarcoma. It is for patients whose cancer has spread to the lungs, bones, bone marrow, or other sites. The main goal is to see if event-free survival is better with ganitumab, and it also looks at overall survival and treatment toxicity, plus many exploratory biomarker and imaging studies to understand how the treatment works. Key exclusions include disease limited to regional lymph nodes, tumors in the brain or spinal cord, prior chemotherapy or radiation, pregnancy or contraception requirements for females of childbearing potential, diabetes, and chronic high-dose corticosteroid use.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options is being studied. Conditions: Solid Tumors, CNS Tumors • Eligibility: Inclusion Criteria: 1. Disease status: * Phase 1 portion (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 * Phase 2 portion: * Part…. Goal: This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Hoffmann-La Roche.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests EGFR-targeted CAR T cell therapy in children and young adults with relapsed or refractory non-CNS solid tumors that express EGFR. It has two arms: Arm A uses EGFR CAR T cells alone, and Arm B adds a CD19-targeting component. It is a phase I, open-label, non-randomized trial to assess safety and feasibility, determine the maximum tolerated dose, describe the toxicity, and see how long the CAR T cells persist and act against tumors. Eligible participants include those with EGFR-expressing non-CNS solid tumors that are recurrent or refractory; early enrollees are ages 15–30, with later enrollees ages 1–30. Key exclusions include active infection, other active cancers, active CNS disease, pregnancy, and GVHD or significant immunosuppression; if severe toxicity occurs, cetuximab or trastuzumab may be used to help eliminate the CAR T cells.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests treatments for Ewing sarcoma family tumors (ESFT) and desmoplastic small round cell tumor (DSRCT) in children and young people. - Participants are split into Group A (standard-risk ESFT under 14, non-pelvic, no metastasis) who get standard chemotherapy with planned local control, and Group B (higher-risk ESFT or DSRCT, including those 14 or older or with pelvic or metastatic disease) who receive a window therapy with temsirolimus, temozolomide, and irinotecan, followed by induction chemotherapy and maintenance. - The study aims to estimate the initial response rate to the Group B window therapy and to measure overall survival, progression-free survival, time to progression, and local control outcomes. - Key exclusions include pregnancy or breastfeeding and a history of another cancer (except certain non-melanoma skin cancers); participants must not have had prior chemotherapy or radiation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) is being studied. Conditions: Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma +4 • Eligibility: Procurement Inclusion Criteria: 1. Evaluable neuroblastoma with persistent or relapsed disease 1. Recurrent disease following completion of aggressive multi-drug frontline therapy. 2. Progressive disease during aggressive multi-drug frontline…. Goal: This study is for patients with neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2. The cancer has either come back after treatment or did not respond to treatment. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Baylor College of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests regorafenib, a broad-spectrum tyrosine kinase inhibitor, in young patients ages 9 to 21 with refractory primary bone tumors like Ewing sarcoma or osteosarcoma. It aims to see whether adding regorafenib to standard treatment can improve outcomes and to use molecular testing to guide therapy and understand prognosis. Participants must have progressed or relapsed after initial therapy and be able to swallow tablets, with informed consent and a life expectancy of at least 12 weeks. Exclusions include prior exposure to regorafenib, pregnancy or breastfeeding, and health conditions that could increase risk or interfere with results.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma is being studied. Conditions: Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor +5 • Eligibility: Inclusion Criteria: All Patients * Previously confirmed (histologically or cytologically) pediatric solid tumor (e.g., neuroblastoma, sarcoma), lymphoma (including Hodgkin's lymphoma), or malignant brain tumors that are clinically or…. Goal: The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Cellectar Biosciences, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests image-guided radiation therapy (IGRT) to treat pediatric musculoskeletal tumors, aiming to target the tumor precisely while sparing healthy tissue. - It is for people up to 25 years old with musculoskeletal tumors of the bone or soft tissue that require radiation to the primary tumor site (including Ewing family, rhabdomyosarcoma, and other soft tissue sarcomas). - The study will estimate local tumor control with IGRT, compare its effectiveness to older non-image-guided radiation, and look at patterns of failure and long-term disease control (over 5 years). - It also investigates how radiation affects normal tissues, such as growth plates and muscles, to identify dose thresholds and track changes over time. - Eligibility notes include that females of childbearing potential must have a negative beta-HCG test, and patients should not have had prior therapeutic irradiation to the primary site (except for a brief emergent dose that can be accounted for in analysis).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study, currently not recruiting, tests whether CDH6 protein levels in osteosarcoma and Ewing’s sarcoma tissue can serve as a prognostic biomarker and help monitor treatment response. It includes patients over 12 years old with newly diagnosed high‑grade osteosarcoma or Ewing’s sarcoma who have not yet received first‑line chemotherapy. Researchers will measure CDH6 expression in tumor samples collected at diagnosis and around surgery to see if changes reflect chemotherapy sensitivity and prognosis. Exclusion criteria include inability to receive standardized chemotherapy and surgery at the center, not agreeing to standard follow‑up, or any condition that could harm participation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests GD2-CART01, a CAR T-cell therapy made from the patient’s own T cells that targets the GD2 protein, in children and young adults with high‑risk or relapsed/refractory neuroblastoma and a small group of other GD2‑positive tumors. - It has two parts: Phase I to find a safe dose and Phase II to expand and assess efficacy. - Eligible participants will have T cells collected, engineered into GD2-CART01, receive a lymphodepleting regimen, and then a single infusion of the CAR T cells that includes a safety switch to stop activity if needed. - The study follows patients for up to 5 years after treatment; key exclusions include pregnancy, severe infections, HIV, hepatitis B or C, and certain organ dysfunction or recent conflicting therapies.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors. is being studied. Conditions: Late Effects, Testicular Germ Cell Tumor Mixed, Non-Metastatic Breast Carcinoma +6 • Eligibility: 1. males and females aged 18-65 years; 2. Diagnosis and management at CLB for one of the following cancers: Hodgkin's lymphoma, aggressive non-Hodgkin's lymphoma, acute myeloid leukemia and…. Goal: INTRODUCTION: Approximately 44% of cancer survivors experience a deteriorated quality of life 5 years after diagnosis due to late onset of complications related to cancer treatments. The objective of the study is to evaluate the incidence rates of treatment-related complications, identify sub-clinical abnormalities and risk factors in patients participating in the PASCA post-treatment program. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Centre Leon Berard.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests cabozantinib s-malate as a treatment for osteosarcoma or Ewing sarcoma that has relapsed or grown after standard therapy. - The study aims to see if cabozantinib can shrink tumors or stop their growth, with a focus on six-month responses measured by RECIST criteria. - It also looks at longer-term outcomes such as progression-free and overall survival, plus safety. - The trial is sponsored by the National Cancer Institute and is currently active but not recruiting. - Key exclusions include prior cabozantinib, recent cancer therapies, untreated brain metastases or major heart problems, pregnancy or breastfeeding, and HIV infection on antiretroviral therapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests adding abemaciclib to the chemotherapy drugs irinotecan and temozolomide for Ewing's sarcoma that has come back or did not respond to treatment. - It is for children and young adults with Ewing's sarcoma or Ewing's sarcoma-like tumors and is part of the CAMPFIRE master protocol to speed up developing new treatments. - The trial aims to learn whether this combination improves outcomes and safety, with participation lasting about 11 months or longer depending on how the tumor responds. - Key exclusions include severe uncontrolled illness, active infections (including HIV or hepatitis), pregnancy or breastfeeding, prior CDK4/6 inhibitor use, and progression during prior irinotecan/temozolomide.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dietary Habits, Metabolome, Immune Profile and Microbiota in Patients With Bone Sarcoma is being studied. Conditions: Osteosarcoma, Ewing Sarcoma • Eligibility: Inclusion Criteria: * Osteosarcoma and Ewing sarcoma first diagnosis * No previous chemotherapy treatment * ≥ 12 years old * Able to understand the questionnaire * No malignant…. Goal: Osteosarcoma and Ewing sarcoma treatment has not changed in the last 30 years. For other types of cancer the epidemiologic and prognostic correlations between dietary behavior, lifestyle and metabolic alterations (i.e.obesity, insulin-resistance) are well known (breast cancer, prostate cancer, colon cancer). Phase/Status/Sponsor: Unknown phase; UNKNOWN; Istituto Ortopedico Rizzoli.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Effect of Gum Chewing or Walking on Bowel Prep Quality and Patient Satisfaction Before Colonoscopy is being studied. Conditions: Colonoscopy, Bowel Preparation • Eligibility: Inclusion Criteria: * Individuals aged between 18 and 65 years, * Capable of effective communication, * Mentally healthy, * Individuals who can comprehend and implement planned interventions before…. Goal: Colorectal cancers are a major global health problem, highlighting the critical importance of screening programs for early diagnosis and effective treatment. The success of colonoscopy largely depends on the quality of bowel preparation. Phase/Status/Sponsor: Unknown phase; COMPLETED; Istanbul University - Cerrahpasa.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies is being studied. Conditions: Postoperative Ileus • Eligibility: Inclusion Criteria: * Women who would undergo surgical staging for malignant gynecologic disease such as endometrial cancer, cervix cancer and ovarian cancer were assessed for eligibility. Exclusion Criteria:…. Goal: Postoperative ileus can cause the accumulation of secretions and gas, resulting in nausea, vomiting and abdominal distension and pain. Prolonged paralytic ileus is one of the commonest reasons for delayed recovery and discharge from hospital following abdominal surgery. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Erzincan Military Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Impact of Oral Cryotherapy and Chewing Gum Interventions is being studied. Conditions: Breast Cancer, Nausea and Vomiting, Quality of Life +1 • Eligibility: Inclusion Criteria: * Women aged between 18 and 65 years, * Scheduled to receive adjuvant chemotherapy for the first time, * Receiving the AC protocol as their chemotherapy…. Goal: Chemotherapy-induced nausea and vomiting (CINV) and taste alterations continue to be among the most common and most severe side effects that women receiving adjuvant chemotherapy for breast cancer suffer. Despite standard antiemetic treatments, a significant proportion of patients experience inadequate symptom management, necessitating investigation into complementary non-pharmacological interventions such as oral cryotherapy and chewing gum in women undergoing Adriamycin-Cyclophosphamide therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Hacettepe University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Vaccine Therapy in Treating Patients With Metastatic Cancer is being studied. Conditions: Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer +8 • Eligibility: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Histologically documented metastatic cancer of one of the following types: Cutaneous melanoma Ocular melanoma Colorectal carcinoma Non-small cell lung cancer Breast carcinoma Sarcoma…. Goal: RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic cancer that has not responded to previous therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Motivational Interviewing to Increase Physical Activity Behaviour in Cancer Patients is being studied. Conditions: Cancer, Breast, Cancer of Colon, Endometrial Cancer • Eligibility: Inclusion Criteria: * breast, endometrial or colorectal cancer * cancer stage ≤ stage III * \> 3 months after primary treatment * \< 24 months after primary treatment…. Goal: Physical activity is not only efficient for primary prevention of several cancer types, but it also plays an important role in cancer survivors. Physical activity after a cancer diagnosis has been associated with reduced overall and cancer-specific mortality. Phase/Status/Sponsor: Unknown phase; COMPLETED; Luxembourg Institute of Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain is being studied. Conditions: Cancer • Eligibility: Inclusion Criteria: * Male or female, ≥ 18 years of age. * Diagnosis of cancer. * Opioid-tolerant. Subjects who were opioid tolerant were those taking ≥ 60 mg…. Goal: This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain. The study medication is administered under the tongue as a simple spray and can be self-administered by patients or assisted by their caregivers. Phase/Status/Sponsor: Unknown phase; COMPLETED; INSYS Therapeutics Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Rehabilitation After Radiotherapy for Prostate Cancer is being studied. Conditions: Urinary Irritative/Incontinence Problems, Bowel Problems, Sexual Problems +2 • Eligibility: Inclusion Criteria: * Patients with localized og locally advanced prostate cancer treated with curative intended radiotherapy at Department of Oncology Odense University Hospital in the period of inclusion…. Goal: This project will test and evaluate a rehabilitation programme, which will empower the mens health and give them resources to face at new everyday life. The project examines if a focused interdisciplinary intervention has influence of the patients generic and specified quality of life after curative radiotherapy due to prostate cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Odense University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ABT-751 in Treating Young Patients With Refractory Solid Tumors is being studied. Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor +6 • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed solid tumor\*, including, but not limited to, the following: * Rhabdomyosarcoma * Other soft tissue sarcomas * Ewing's sarcoma family of tumors *…. Goal: RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects of ABT-751 in treating young patients with refractory solid tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Institutes of Health Clinical Center (CC).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma is being studied. Conditions: Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed malignancy that is metastatic or unresectable and for which no effective standard curative or palliative therapy exists * Brain metastases allowed provided both…. Goal: RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid tumors or lymphoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Institutes of Health Clinical Center (CC).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer is being studied. Conditions: Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed malignancy not amenable to curative surgery, radiotherapy, or chemotherapy * Tumor types may include any of the following: * Any solid tumor including,…. Goal: RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase/Status/Sponsor: Unknown phase; COMPLETED; Case Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases is being studied. Conditions: Adult Rhabdomyosarcoma, Lung Metastases, Metastatic Ewing Sarcoma +9 • Eligibility: Inclusion Criteria: * Patients may have a Wilms tumor, Ewing Sarcoma, Rhabdomyosarcoma or any other metastatic pediatric malignancy; patients may have a single or multiple pulmonary metastases at…. Goal: This pilot clinical trial studies intensity-modulated radiation therapy (IMRT) in treating younger patients with lung metastases. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Phase/Status/Sponsor: Unknown phase; COMPLETED; Ann & Robert H Lurie Children's Hospital of Chicago.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Motivational Interviewing as an Intervention for PCOS is being studied. Conditions: Polycystic Ovary Syndrome, Overweight and Obesity, Motivation • Eligibility: Inclusion Criteria: * Women with polycystic ovary syndrome and BMI above 30 kg/m2 Exclusion Criteria: * Women taking gender hormone medication, for example birthcontrol pills. * Metformin treatment…. Goal: The aim of the study is to examine if motivational interviewing can have a positive effect on weight loss over a 6 month period. By losing weight, the investigators assume the patients will have a positive effect on quality of life, and also that weight loss will help to regulate the factors that are present with polycystic ovary syndrom (PCOS); such as menstrual disorders and infertility. Phase/Status/Sponsor: Unknown phase; COMPLETED; Odense University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas is being studied. Conditions: Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Diffuse Large Cell Lymphoma +26 • Eligibility: Inclusion Criteria: * Histologically confirmed refractory malignant solid tumor or lymphoma * Intrinsic brain stem tumors and optic pathway tumors do not require histologic verification * No known…. Goal: This phase I trial is studying the side effects and best dose of oxaliplatin when given together with irinotecan in treating young patients with refractory solid tumors or lymphomas. Drugs used in chemotherapy, such as oxaliplatin and irinotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer is being studied. Conditions: Cancer • Eligibility: INCLUSION CRITERIA: * ≥ 2 years and ≤ 21 years of age at the time of study entry * Scheduled to receive chemotherapy for: * Newly diagnosed: *…. Goal: RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients receiving chemotherapy for cancer. Phase/Status/Sponsor: Unknown phase; TERMINATED; University of South Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.